{"id":"W2742102900","doi":"10.1158/1538-7445.am2017-ct047","title":"Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Veliparib; PARP inhibitor; Medicine; Neutropenia; Febrile neutropenia; Mucositis; Internal medicine; Oncology; Nausea; Pharmacology; Chemotherapy; Poly ADP ribose polymerase; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007841483,0.001099565,0.001652339,0.0004185277,0.0004278243,0.0006774347,0.0005881885,0.0005093371,0.002330534],"category_scores_gemma":[0.0004982428,0.0004455666,0.0006746667,0.0004312363,0.0007352991,0.0004104262,0.0003332473,0.002233838,0.0006133386],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008906811,"about_ca_system_score_gemma":0.001574659,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009759329,"about_ca_topic_score_gemma":0.002288554,"domain_scores_codex":[0.9996928,0.0001359814,0.00002124473,0.00004926169,0.00003485729,0.00006596219],"domain_scores_gemma":[0.9996019,0.00005957191,0.00007264978,0.00003437868,0.00002779457,0.0002037718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5437804,0.107223,0.0184566,0.001079222,0.001161252,0.0007404029,0.0004992515,0.007216565,0.1551393,0.0005205786,0.005420745,0.1587627],"study_design_scores_gemma":[0.2865981,0.6731067,0.02236757,0.00004224237,0.0003481508,0.0006312812,0.00007540758,0.002237561,0.0111476,0.0001922459,0.003208992,0.00004416488],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955351,0.001034863,0.0003429969,0.0001754651,0.00004385204,0.001358808,0.000618198,0.00004896455,0.0008415988],"genre_scores_gemma":[0.9926366,0.0008432115,0.00185128,0.0003509713,0.00008456948,0.001473782,0.001471674,0.00001500227,0.001272921],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002330534,"threshold_uncertainty_score":0.007796466,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04430193968758227,"score_gpt":0.4081689631978827,"score_spread":0.3638670235103004,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}